Latest Breaking News On - Updated results - Page 1 : comparemela.com

GILEAD AND KITE ONCOLOGY TO HIGHLIGHT BROAD AND DIVERSE ONCOLOGY PORTFOLIO AT ASCO 2024

GILEAD AND KITE ONCOLOGY TO HIGHLIGHT BROAD AND DIVERSE ONCOLOGY PORTFOLIO AT ASCO 2024
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Foster cityUnited statesUnited kingdomSanta monicaBrexucabtagene autoleucelAxicabtagene ciloleucelSacituzumab govitecanSacituzumab govitecan hziyEuropean medicines agencyGilead companySmall cell lung cancer development program dataBig ten cancer research consortium studyGuangzhou gloria biosciences coGilead sciences incAmerican society of clinical oncologyEuropean commission

HOOKIPA Pharma Inc (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab

HOOKIPA Pharma Inc (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJoern aldagMichael kaiserHookipa pharma incAmerican society of clinical oncologyPharma incDrug administrationUniversity of chicago medicineExchange commissionEuropean society for medical oncology annual congressCompany typeEuropean medicines agencyHuman papillomavirusAmerican societyClinical oncologyChief executive officer

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or.

United statesJoern aldagMichael kaiserEuropean society for medical oncology annual congressCompany typePharma incDrug administrationAmerican society of clinical oncologyExchange commissionUniversity of chicago medicineEuropean medicines agencyHuman papillomavirusAmerican societyClinical oncologyChief executive officerEuropean medicines

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesJoern aldagMichael kaiserAmerican society of clinical oncologyEuropean society for medical oncology annual congressDrug administrationExchange commissionUniversity of chicago medicineEuropean medicines agencyCompany typePharma incAnnounces pivotal phaseHuman papillomavirusAmerican societyClinical oncologyChief executive officer

Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

SEATTLE (BUSINESS WIRE) Apr 10, 2024

United statesBuenos airesDistrito federalJames tumlinAlpine immune sciencesNephronet clinical trials consortiumBuenos aires convention centerExchange commissionSecurities exchangeVertex pharmaceuticals incorporatedWorld congressAlpine immune sciences incImmune sciencesClinically meaningfulIga nephropathyBusiness wire